Chan, J. F.-W. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514–523 (2020). An early report of the epidemiological, clinical and microbiological features of patients in a family cluster who became ill with an unexplained pneumonia, demonstrating person-to-person spread of a novel coronavirus.
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020). One of the first reports of SARS-CoV-2 identified in Wuhan, China, among hospitalized patients, with whole-genome sequencing, direct PCR and culture from bronchoalveolar lavage fluid confirming a novel type of coronavirus.
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
World Health Organization. Coronavirus Disease (COVID-19) Pandemic. WHO https://www.who.int/europe/emergencies/situations/covid-19 (2025).
Centers for Disease Control and Prevention. CDC Museum COVID-19 Timeline. CDC https://www.cdc.gov/museum/timeline/covid19.html (2023).
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536 (2020).
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
Cao, C. et al. The architecture of the SARS-CoV-2 RNA genome inside virion. Nat. Commun. 12, 3917 (2021).
World Health Organization. WHO COVID-19 dashboard. COVID-19 deaths. WHO https://data.who.int/dashboards/covid19/deaths?n=o (2025).
Bradshaw, D., Dorrington, R., Laubscher, R., Groenewald, P. & Moultrie, T. COVID-19 and all-cause mortality in South Africa — the hidden deaths in the first four waves. S. Afr. J. Sci. https://doi.org/10.17159/sajs.2022/13300 (2022).
Msemburi, W. et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613, 130–137 (2023).
Starke, K. R. et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob. Health 6, e006434 (2021).
Centers for Disease Control and Prevention. COVID-19 Provisional Counts – Weekly Updates by Select Demographic and Geographic Characteristics. CDC https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm (2023).
Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol. 20, 442–447 (2020).
Dudley, J. P. & Lee, N. T. Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea. Clin. Infect. Dis. 71, 863–865 (2020).
Márquez, E. J. et al. Sexual-dimorphism in human immune system aging. Nat. Commun. 11, 751 (2020).
Piasecka, B. et al. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proc. Natl Acad. Sci. USA 115, E488–E497 (2018).
Schurz, H. et al. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum. Genomics 13, 2 (2019).
Moore, J. T. et al. Disparities in incidence of COVID-19 among underrepresented racial/ethnic groups in counties identified as hotspots during June 5-18, 2020 – 22 states, February-June 2020. MMWR Morb. Mortal. Wkly Rep. 69, 1122–1126 (2020).
Figueroa, J. F. et al. Association of race, ethnicity, and community-level factors with COVID-19 cases and deaths across U.S. counties. Healthcare 9, 100495 (2021).
Jassat, W. et al. Corrigendum: The intersection of age, sex, race and socio-economic status in COVID-19 hospital admissions and deaths in South Africa. S. Afr. J. Sci. https://doi.org/10.17159/sajs.2022/13323C (2022).
Marshall, J. C. et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 20, e192–e197 (2020).
Docherty, A. B. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ 369, m1985 (2020).
Guan, W. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020). This study evaluated confirmed cases of COVID-19 in over 550 hospitals in mainland China and was one of the first to characterize the range of symptomatology that occurs due to SARS-CoV-2 infection.
Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436 (2020).
Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19. CDC https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (2020).
Kompaniyets, L. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prev. Chronic Dis. 18, E66 (2021).
Mara, G., Nini, G. & Cotoraci, C. Impact of pulmonary comorbidities on COVID-19: acute and long-term evaluations. J. Clin. Med. 14, 1446 (2025).
Jassat, W. et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV 8, e554–e567 (2021).
Vijenthira, A. et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136, 2881–2892 (2020).
Fisher, A. M. et al. Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. Clin. Transplant. 35, e14216 (2021).
Turtle, L. et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Med. 20, e1004086 (2023).
Andersen, K. M. et al. Association between chronic use of immunosuppresive drugs and clinical outcomes from coronavirus disease 2019 (COVID-19) hospitalization: a retrospective cohort study in a large US health system. Clin. Infect. Dis. 73, e4124–e4130 (2021).
Barnett, K. et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380, 37–43 (2012).
Russell, C. D., Lone, N. I. & Baillie, J. K. Comorbidities, multimorbidity and COVID-19. Nat. Med. 29, 334–343 (2023).
Chudasama, Y. V. et al. Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K. BMC Infect. Dis. 21, 908 (2021).
Carmona-Pírez, J. et al. Identifying multimorbidity profiles associated with COVID-19 severity in chronic patients using network analysis in the PRECOVID Study. Sci. Rep. 12, 2831 (2022).
Delerue Matos, A., Fonseca de Paiva, A., Cunha, C. & Voss, G. Precautionary behaviours of individuals with multimorbidity during the COVID-19 pandemic. Eur. J. Ageing 19, 827–835 (2022).
Centers for Disease Control and Prevention. COVID Data Tracker 2023. CDC https://covid.cdc.gov/covid-data-tracker (2023).
Clark, E. C. et al. Changes to public health surveillance methods due to the COVID-19 pandemic: scoping review. JMIR Public Health Surveill. 10, e49185 (2024).
Ibrahim, N. K. Epidemiologic surveillance for controlling Covid-19 pandemic: types, challenges and implications. J. Infect. Public Health 13, 1630–1638 (2020).
World Health Organization. Statement on the Update of WHO’s Working Definitions and Tracking System for SARS-CoV-2 Variants of Concern and Variants of Interest. WHO https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest (2023).
World Health Organization. Updated Working Definitions and Primary Actions for SARS-CoV-2 Variants. WHO https://www.who.int/publications/m/item/updated-working-definitions-and-primary-actions-for–sars-cov-2-variants (2023).
Sanjuán, R., Nebot, M. R., Chirico, N., Mansky, L. M. & Belshaw, R. Viral mutation rates. J. Virol. 84, 9733–9748 (2010).
Nobusawa, E. & Sato, K. Comparison of the mutation rates of human influenza A and B viruses. J. Virol. 80, 3675–3678 (2006).
Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361–379 (2023).
DeGrace, M. M. et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature 605, 640–652 (2022). As novel SARS-CoV-2 variants emerged, the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme was established, which was a model of how to develop a coordinated approach to identify emerging variants, immune escape and protection, and predicted effects on vaccine protection.
Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021).
Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021).
Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021).
Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature 596, 276–280 (2021).
Rashedi, R. et al. Delta variant: the new challenge of COVID-19 pandemic, an overview of epidemiological, clinical, and immune characteristics. Acta Biomed. 93, e2022179 (2022).
Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature 603, 679–686 (2022).
Saito, A. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe 30, 1540–1555.e15 (2022).
Gorbalenya, A. E. et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
LaTourrette, K., Holste, N. M., Rodriguez-Peña, R., Leme, R. A. & Garcia-Ruiz, H. Genome-wide variation in Betacoronaviruses. J. Virol. 95, e00496 (2021).
Zhou, H. et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell 184, 4380–4391.e14 (2021).
Wacharapluesadee, S. et al. Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nat. Commun. 12, 972 (2021).
Xiao, K. et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature 583, 286–289 (2020).
Stertz, S. et al. The intracellular sites of early replication and budding of SARS-coronavirus. Virology 361, 304–315 (2007).
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 (2021).
Matsuyama, S. et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 84, 12658–12664 (2010).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 23, 21–39 (2022).
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B Betacoronaviruses. Nat. Microbiol. 5, 562–569 (2020).
Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016–1035.e19 (2020).
Beyerstedt, S., Casaro, E. B. & Rangel, É. B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 40, 905–919 (2021).
Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418 (2020).
Li, H. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395, 1517–1520 (2020).
Li, S. et al. SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-induced inflammatory responses. Cell Res. 33, 201–214 (2023).
Van Cleemput, J. et al. Organ-specific genome diversity of replication-competent SARS-CoV-2. Nat. Commun. 12, 6612 (2021).
Jacobs, J. L. et al. Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19. J. Infect. Dis. 226, 2089–2094 (2022).
Hagman, K. et al. Prevalence and clinical relevance of viraemia in viral respiratory tract infections: a systematic review. Lancet Microbe 6, 100967 (2025).
Znaidia, M., Demeret, C., van der Werf, S. & Komarova, A. V. Characterization of SARS-CoV-2 evasion: interferon pathway and therapeutic options. Viruses 14, 1247 (2022).
Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9 (2020).
Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Sci 369, 718–724 (2020).
Lee, J. S. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 5, eabd1554 (2020).
Zhou, Y. et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci. Rev. 7, 998–1002 (2020).
Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 17, 533–535 (2020).
Schulte-Schrepping, J. et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182, 1419–1440.e23 (2020).
Sinha, P., Matthay, M. A. & Calfee, C. S. Is a ‘cytokine storm’ relevant to COVID-19? JAMA Intern. Med. 180, 1152–1154 (2020).
Kox, M., Waalders, N. J. B., Kooistra, E. J., Gerretsen, J. & Pickkers, P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA 324, 1565–1567 (2020).
Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636–1643 (2020).
Ramlall, V. et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 26, 1609–1615 (2020).
Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N. Engl. J. Med. 383, 120–128 (2020).
Pfeiler, S., Massberg, S. & Engelmann, B. Biological basis and pathological relevance of microvascular thrombosis. Thromb. Res. 133 (Suppl. 1), S35–S37 (2014).
Louis, T. J., Qasem, A., Abdelli, L. S. & Naser, S. A. Extra-pulmonary complications in SARS-CoV-2 infection: a comprehensive multi organ-system review. Microorganisms 10, 153 (2022).
Langford, B. J. et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin. Microbiol. Infect. 26, 1622–1629 (2020).
Zuo, W. et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect. Dis. 24, 845–855 (2024).
Tomasicchio, M. et al. SARS-CoV-2 viral replication persists in the human lung for several weeks after symptom onset. Am. J. Respir. Crit. Care Med. 209, 840–851 (2004).
Raglow, Z. et al. SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis. Lancet Microbe 5, e235–e246 (2024).
Hettle, D., Hutchings, S., Muir, P. & Moran, E. Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: retrospective cohort study and literature review. Clin. Infect. Pract. 16, 100210 (2022).
Xu, J. et al. Chronic active SARS-CoV-2 in B-cell immunodeficiency. Innov. Med. 2, 100071 (2024).
Ma, Q. et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw. Open 4, e2137257 (2021).
Struyf, T. et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst. Rev. 7, CD013665 (2020).
Iuliano, A. D. Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods — United States, December 2020–January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 146–152 (2022).
Miller, J. M. et al. Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin. Infect. Dis. https://doi.org/10.1093/cid/ciae104 (2024).
Fragkou, P. C. et al. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. Clin. Microbiol. Infect. 28, 812–822 (2022).
Barak, N. et al. Lessons from applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests. Sci. Transl. Med. 13, eabf2823 (2021).
Kidd, M. et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral load in samples tested by taqpath polymerase chain reaction. J. Infect. Dis. 223, 1666–1670 (2021).
Chu, V. T. et al. Comparison of home antigen testing with RT-PCR and viral culture during the course of SARS-CoV-2 infection. JAMA Intern. Med. 182, 701–709 (2022).
Hirabayashi, E. et al. Comparison of diagnostic accuracy of rapid antigen tests for COVID-19 compared to the viral genetic test in adults: a systematic review and meta-analysis. JBI Evid. Synth. 22, 1939–2002 (2024).
Hayden, M. K. et al. The Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing (January 2023). Clin. Infect. Dis. 78, e350–e384 (2024).
Soni, A. et al. Performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection: a prospective cohort study. Ann. Intern. Med. 176, 975–982 (2023).
Frank, F. et al. Deep mutational scanning identifies SARS-CoV-2 nucleocapsid escape mutations of currently available rapid antigen tests. Cell 185, 3603–3616.e13 (2022).
Del Vecchio, C. et al. Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants. Nat. Commun. 13, 5870 (2022).
To, K. K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565–574 (2020).
Yong, S. E. F. et al. Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infect. Dis. 20, 809–815 (2020).
Chen, L.-L. et al. Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong. Nat. Commun. 13, 3618 (2022).
Yang, Y. et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat. Microbiol. 7, 423–433 (2022).
Peto, L. et al. Diagnosis of SARS-CoV-2 infection with LamPORE, a high-throughput platform combining loop-mediated isothermal amplification and nanopore sequencing. J. Clin. Microbiol. 59, e03271-20 (2021).
Lam, C. et al. SARS-CoV-2 genome sequencing methods differ in their abilities to detect variants from low-viral-load samples. J. Clin. Microbiol. 59, e0104621 (2021).
Miller, J. M. et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin. Infect. Dis. 67, e1 (2018).
Tsang, N. N. Y. et al. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect. Dis. 21, 1233–1245 (2021).
Xie, J.-W. et al. Nasal swab is a good alternative sample for detecting SARS-CoV-2 with rapid antigen test: a meta-analysis. Travel Med. Infect. Dis. 52, 102548 (2023).
Waggoner, J. J. et al. Concordance of SARS-CoV-2 results in Self-collected nasal swabs vs swabs collected by health care workers in children and adolescents. JAMA 328, 935–940 (2022).
Baron, A. et al. Bronchoalveolar lavage in patients with COVID-19 with invasive mechanical ventilation for acute respiratory distress syndrome. Ann. Am. Thorac. Soc. 18, 723–726 (2021).
Laxton, C. S. et al. The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity. Lancet Microbe 4, e837–e850 (2023).
Watkins, A. E. et al. Increased SARS-CoV-2 testing capacity with pooled saliva samples. Emerg. Infect. Dis. 27, 1184–1187 (2021).
Butler-Laporte, G. et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern. Med. 181, 353–360 (2021).
Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2. CDC https://www.cdc.gov/covid/hcp/clinical-care/overview-testing-sars-cov-2.html (2025).
Total COVID-19 vaccine doses administered. Our World in Data https://ourworldindata.org/grapher/cumulative-covid-vaccinations?tab=table (2025).
Lives saved by COVID-19 vaccines. J. Paediatr. Child Health 222, 2129 (2022).
World Health Organization. WHO COVID-19 Dashboard. COVID-19 vaccination, world data. WHO https://data.who.int/dashboards/covid19/vaccines (2025).
BC Centre for Disease Control. World Health Organization (WHO) Emergency Use Authorization (EUA) Qualified COVID-19 Vaccines. WHO https://www.bccdc.ca/Health-Info-Site/Documents/COVID-19_vaccine/WHO-EUA-qualified-covid-vaccines.pdf (2024).
World Health Organization. WHO Roadmap on Uses of COVID-19 Vaccines in the Context of Omicron and High Population Immunity. WHO https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2 (2023).
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021). The pivotal phase III study demonstrated that the mRNA-1273 vaccine provided 94.1% efficacy against COVID-19 illness and provided essential data to proceed to Emergency Use Authorization and licensure.
Falsey, A. R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N. Engl. J. Med. 385, 2348–2360 (2021). The phase III study demonstrated that the AZD1222 vaccine had an overall vaccine efficacy of 74% and a vaccine efficacy of 83.5% in adults >65 years of age.
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). This pivotal phase III study demonstrated that the BNT162b2 vaccine provided 95% efficacy against COVID-19 in persons aged ≥16 years and provided essential data to proceed to Emergency Use Authorization and licensure.
Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172–1183 (2021). This phase III study demonstrated that the recombinant nanoparticle vaccine NVX-CoV2373 provided 89.7% efficacy against COVID-19 in adults 18–84 years of age.
Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021). This phase III study demonstrated that a single dose of the recombinant human adenovirus vector type 26 SARS-CoV-2 vaccine provided 66.9% efficacy against COVID-19 in adults ≥18 years of age.
Dayan, G. H. et al. Efficacy of a bivalent (D614+B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Lancet Respir. Med. 11, 975–990 (2023).
Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).
Branche, A. R. et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat. Med. 29, 2334–2346 (2023).
US Food and Drug Administration. Novavax COVID-19 vaccine, adjuvanted. FDA https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted (2025).
US Food and Drug Administration. FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently (2024).
Menegale, F. et al. Evaluation of waning of SARS-CoV-2 vaccine–induced immunity: a systematic review and meta-analysis. JAMA Netw. Open 6, e2310650 (2023).
Nordström, P., Ballin, M. & Nordström, A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect. Dis. 22, 781–790 (2022).
Arbel, R. et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect. Dis. 23, 914–921 (2023).
Centers for Disease Control and Prevention. Vaccines for Moderately to Severely Immunocompromised People. CDC https://www.cdc.gov/covid/vaccines/immunocompromised-people.html (2025).
Mayr, F. B., Talisa, V. B., Shaikh, O., Yende, S. & Butt, A. A. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. N. Engl. J. Med. 386, 1375–1377 (2022).
Atmar, R. L. et al. Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med. 386, 1046–1057 (2022).
Lazarus, R. et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet 398, 2277 (2021).
Debes, A. K. et al. Association of vaccine type and prior SARS-CoV-2 Infection with symptoms and antibody measurements following vaccination among health care workers. JAMA Intern. Med. 181, 1660–1662 (2021).
Karlstad, Ø. et al. SARS-CoV-2 vaccination and myocarditis in a nordic cohort study of 23 million residents. JAMA Cardiol. 7, 600–612 (2022).
Buchan, S. A. et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw. Open 5, e2218505 (2022).
Su, J. R. Myopericarditis following COVID-19 vaccination : updates from the Vaccine Adverse Event Reporting System (VAERS). CDC https://stacks.cdc.gov/view/cdc/109492 (2021).
Jeong, Y. D. et al. Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023. Sci. Rep. 14, 24561 (2024).
Obeid, M. et al. Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2022.0446 (2022).
Sherman, A. C. et al. Severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines in allogeneic hematopoietic stem cell transplant recipients: immunogenicity and reactogenicity. Clin. Infect. Dis. 75, e920–e923 (2021).
Ghione, P. et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies. Blood 138, 811–814 (2021).
Cowan, J., Amson, A., Christofides, A. & Chagla, Z. Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations. Int. J. Infect. Dis. 134, 228–238 (2023).
Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553–556 (2022).
Choudhary, M. C. et al. Emergence of SARS-CoV-2 escape mutations during bamlanivimab therapy in a phase II randomized clinical trial. Nat. Microbiol. 7, 1906–1917 (2022).
Schmidt, P., Li, Y. & Popejoy, M. Immunobridging for pemivibart, a monoclonal antibody for prevention of Covid-19. N. Engl. J. Med. 391, 1860–1862 (2024).
Lam, C. & Patel, P. Nirmatrelvir-Ritonavir. StatPearls [Internet] https://www.ncbi.nlm.nih.gov/books/NBK585126/ (updated 8 August 2023).
Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022). A phase II–III double-blind, randomized, controlled trial in unvaccinated, non-hospitalized adults at high risk for progression to severe COVID-19, that showed a significant decrease in risk of progression to severe COVID-19 in the nirmatrelvir-ritonavir group.
Hammond, J. et al. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. N. Engl. J. Med. 390, 1186–1195 (2024).
Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022).
Butler, C. C. et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 401, 281–293 (2023).
National Institute for Health and Care Excellence. Evidence Review for Molnupiravir: NICE COVID-19 Rapid Guideline: Managing COVID-19: Evidence Review Q (NICE, 2022).
Gupta, A. et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 327, 1236–1246 (2022).
Focosi, D., Casadevall, A., Franchini, M. & Maggi, F. Sotrovimab: a review of its efficacy against SARS-CoV-2 variants. Viruses 16, 217 (2024).
Montgomery, H. et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 10, 985–996 (2022).
Ragonnet-Cronin, M. et al. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy. Nat. Commun. 14, 3334 (2023).
Nielsen, F. M. et al. Lower vs higher oxygenation target and days alive without life support in COVID-19: the HOT-COVID randomized clinical trial. JAMA 331, 1185–1194 (2024).
Cajanding, R. Oxygen use and saturation targets in patients with COVID-19: Are we giving too much or aiming too low? Nurs. Crit. Care 27, 282–285 (2022).
Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 — final report. N. Engl. J. Med. 383, 1813–1826 (2020). The double-blind, randomized, placebo-controlled trial of intravenous remdesivir as compared with placebo in hospitalized adults with COVID-19, demonstrating that remdesivir was superior to placebo in shortening the time to recovery from infection.
Pan, H. et al. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399, 1941–1953 (2022).
Amstutz, A. et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir. Med. 11, 453–464 (2023).
Mozaffari, E. et al. Remdesivir is associated with reduced mortality in COVID-19 patients requiring supplemental oxygen including invasive mechanical ventilation across SARS-CoV-2 variants. Open Forum Infect. Dis. 10, ofad482 (2023).
Paules, C. I. et al. A risk profile using simple hematologic parameters to assess benefits from baricitinib in patients hospitalized with COVID-19: a post hoc analysis of the adaptive COVID-19 treatment trial-2. Ann. Intern. Med. 177, 343–352 (2024).
Singh, K. et al. SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir. J. Infect. Dis. 230, 624–634 (2024).
Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305–315 (2022).
RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021).
Covello, R. D. et al. Meta-analysis of glucocorticoids for Covid-19 patients not receiving oxygen. NEJM Evid. 2, EVIDoa2200283 (2023).
Angus, D. C. et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 324, 1317–1329 (2020).
Sterne, J. A. C. et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA 324, 1330–1341 (2020).
The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).
Godolphin, P. J. et al. Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: a network meta-analysis. PLoS ONE 17, e0270668 (2022).
Rosas, I. O. et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 47, 1258–1270 (2021).
MArconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9, 1407–1418 (2021).
Ely, E. W. et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir. Med. 10, 327–336 (2022).
Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795–807 (2021).
RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400, 359–368 (2022).
Amstutz, A. et al. Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials. Lancet Respir. Med. 13, 530–544 (2025).
RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 665–676 (2022).
The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19. N. Engl. J. Med. 385, 790–802 (2021).
Stone, G. W. et al. Randomized trial of anticoagulation strategies for noncritically Ill patients hospitalized with COVID-19. JACC 81, 1747–1762 (2023).
Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397, 2253–2263 (2021).
Bradbury, C. A., Lawler, P. R., McVerry, B. J., Zarychanski, R. & REMAP-C. A. P. Investigators. Continuation of therapeutic dose heparin for critically ill patients with COVID-19. Intensive Care Med. 49, 873–875 (2023).
Goligher, E. C. et al. Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19. JAMA 329, 1066–1077 (2023).
RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 143–151 (2022).
REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support in critically Ill patients with COVID-19. JAMA 327, 1247–1259 (2022).
Berger, J. S. et al. Effect of P2Y12 inhibitors on survival free of organ support among hospitalized patients with COVID-19. JAMA Netw. Open 6, e2314428 (2023).
Writing Committee for the REMAP-CAP Investigators. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA 329, 39–51 (2023).
Calfee, C. S. et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir. Med. 6, 691–698 (2018).
Lao, U.-S., Law, C.-F., Baptista-Hon, D. T. & Tomlinson, B. Systematic review and meta-analysis of statin use and mortality, intensive care unit admission and requirement for mechanical ventilation in COVID-19 patients. J. Clin. Med. 11, 5454 (2022).
The REMAP-CAP Investigators. Simvastatin in critically Ill patients with Covid-19. N. Engl. J. Med. 389, 2341–2354 (2023).
Evans, R. A. et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg. Health Eur. 35, 100747 (2023).
Little, J. S. et al. Protracted SARS-CoV-2 infection in B-cell depleted patients: immunologic andiral characteristics and response to dual and extended antiviral therapy. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaf383 (2025).
Weinstein, E. et al. Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(25)00221-X (2025).
Axfors, C. et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect. Dis. 21, 1170 (2021).
RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397, 2049–2059 (2021).
Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support–free days in critically Ill patients with COVID-19 a randomized clinical trial. JAMA 326, 1690–1702 (2021).
Misset, B. et al. Convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients. N. Engl. J. Med. 389, 1590–1600 (2023).
Senefeld, J. W. et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients. JAMA Netw. Open 6, e2250647 (2023).
Huygens, S. et al. Clinical and virological outcome of monoclonal antibody therapies across SARS-CoV-2 variants in 245 immunocompromised patients: a multicenter prospective cohort study. Clin. Infect. Dis. 78, 1514–1521 (2024).
Allotey, J. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 370, m3320 (2020).
Chourasia, P. et al. Paxlovid (Nirmatrelvir and Ritonavir) use in pregnant and lactating woman: current evidence and practice guidelines — a scoping review. Vaccines 11, 107 (2023).
Uktis. Medications Used to Treat Covid 19 in Pregnancy. Uktis https://uktis.org/monographs/medications-used-to-treat-covid-19-in-pregnancy/ (2025).
Jorgensen, S. C. J. & Lapinsky, S. E. Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review. Clin. Microbiol. Infect. 28, 51–57 (2022).
Nana, M. et al. Use of interleukin-6 receptor antibodies in the second and third trimester of pregnancy: a retrospective cohort study. Lancet Rheumatol. 6, e625–e635 (2024).
Ferreira, L. N., Pereira, L. N., da Fé Brás, M. & Ilchuk, K. Quality of life under the COVID-19 quarantine. Qual. Life Res. 30, 1389–1405 (2021).
Chu, I. Y.-H., Alam, P., Larson, H. J. & Lin, L. Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response. J. Travel. Med. 27, taaa192 (2020).
Long, D. et al. Health-related quality of life and mental well-being of healthy and diseased persons in 8 countries: does stringency of government response against early COVID-19 matter? SSM Popul. Health 15, 100913 (2021).
Yin, S., Njai, R., Barker, L., Siegel, P. Z. & Liao, Y. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. Popul. Health Metr. 14, 22 (2016).
EQ-5D-5L – EQ-5D. EUROQOL https://euroqol.org/register/obtain-eq-5d/available-versions/ (2025).
Ware, J. E. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med. Care 30, 473–483 (1992).
Nandasena, H. M. R. K. G., Pathirathna, M. L., Atapattu, A. M. M. P. & Prasanga, P. T. S. Quality of life of COVID 19 patients after discharge: systematic review. PLoS ONE 17, e0263941 (2022).
Poudel, A. N. et al. Impact of Covid-19 on health-related quality of life of patients: a structured review. PLoS ONE 16, e0259164 (2021).
van der Molen, T. et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcomes 1, 13 (2003).
Jones, P. W., Quirk, F. H. & Baveystock, C. M. The St George’s Respiratory Questionnaire. Respir. Med. 85, 25–31 (1991).
Herdman, M. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20, 1727–1736 (2011).
Hay, J. W. et al. A US population health survey on the impact of COVID-19 using the EQ-5D-5L. J. Gen. Intern. Med. 36, 1292–1301 (2021).
Lubetkin, E. I., Long, D., Haagsma, J. A., Janssen, M. F. & Bonsel, G. J. Health inequities as measured by the EQ-5D-5L during COVID-19: results from New York in healthy and diseased persons. PLoS ONE 17, e0272252 (2022).
Ping, W. et al. Evaluation of health-related quality of life using EQ-5D in China during the COVID-19 pandemic. PLoS ONE 15, e0234850 (2020).
Barani, S. et al. Health-related quality of life among COVID-19 individuals: a cross-sectional study in Tamil Nadu, India. Clin. Epidemiol. Glob. Health 13, 100943 (2022).
Violato, M. et al. The COVID-19 pandemic and health-related quality of life across 13 high- and low-middle-income countries: a cross-sectional analysis. PLoS Med. 20, e1004146 (2023).
Aburto, J. M. et al. Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a population-level study of 29 countries. Int. J. Epidemiol. 51, 63–74 (2022).
Heuveline, P. & Tzen, M. Beyond deaths per capita: comparative COVID-19 mortality indicators. BMJ Open 11, e042934 (2021).
Andrasfay, T. & Goldman, N. Reductions in US life expectancy during the COVID-19 pandemic by race and ethnicity: is 2021 a repetition of 2020? PLoS ONE 17, e0272973 (2022).
Andrasfay, T. & Goldman, N. Association of the COVID-19 pandemic with estimated life expectancy by race/ethnicity in the United States, 2020. JAMA Netw. Open 4, e2114520 (2021).
Woolf, S. H., Masters, R. K. & Aron, L. Y. Effect of the covid-19 pandemic in 2020 on life expectancy across populations in the USA and other high income countries: simulations of provisional mortality data. BMJ 373, n1343 (2021).
Huang, G. et al. The effect of the COVID-19 pandemic on life expectancy in 27 countries. Sci. Rep. 13, 8911 (2023).
United Nations. World Population Prospects 2019: Highlights. United Nations https://population.un.org/wpp/ (2024).
Islam, N. et al. Effects of covid-19 pandemic on life expectancy and premature mortality in 2020: time series analysis in 37 countries. BMJ 375, e066768 (2021).
Lytras, S., Xia, W., Hughes, J., Jiang, X. & Robertson, D. L. The animal origin of SARS-CoV-2. Science 373, 968–970 (2021).
Ellwanger, J. H. & Chies, J. A. B. Zoonotic spillover: understanding basic aspects for better prevention. Genet. Mol. Biol. 44, e20200355 (2021).
Kessler, S., Harder, T. C., Schwemmle, M. & Ciminski, K. Influenza a viruses and zoonotic events — are we creating our own reservoirs? Viruses 13, 2250 (2021).
Kawasaki, J., Suzuki, T. & Hamada, M. Hidden challenges in evaluating spillover risk of zoonotic viruses using machine learning models. Commun. Med. 5, 187 (2025).
Xiao, X., Newman, C., Buesching, C. D., Macdonald, D. W. & Zhou, Z.-M. Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic. Sci. Rep. 11, 11898 (2021).
World Health Organization. One Health. WHO https://www.who.int/health-topics/one-health (2025).
Centers for Disease Control and Prevention (CDC). Update: outbreak of severe acute respiratory syndrome — worldwide, 2003. MMWR Morb. Mortal. Wkly. Rep. 52, 241–246, 248 (2003).
Olsen, S. J. et al. Transmission of the severe acute respiratory syndrome on aircraft. N. Engl. J. Med. 349, 2416–2422 (2003).
Fang, Y., Nie, Y. & Penny, M. Transmission dynamics of the COVID-19 outbreak and effectiveness of government interventions: a data-driven analysis. J. Med. Virol. 92, 645 (2020).
Kucharski, A. J. et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect. Dis. 20, 553 (2020).
Akhmetzhanov, A. R. et al. Transmission dynamics and effectiveness of control measures during COVID-19 surge, Taiwan, April–August 2021. Emerg. Infect. Dis. 28, 2051–2059 (2022).
Chernozhukov, V., Kasahara, H. & Schrimpf, P. The association of opening K-12 schools with the spread of COVID-19 in the United States: county-level panel data analysis. Proc. Natl Acad. Sci. USA 118, e2103420118 (2021).
Cevik, M., Kuppalli, K., Kindrachuk, J. & Peiris, M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 371, m3862 (2020).
Gilbert, P. B. et al. A Covid-19 milestone attained — a correlate of protection for vaccines. N. Engl. J. Med. 387, 2203–2206 (2022).
Sherman, A. C., Desjardins, M. & Baden, L. R. Vaccine-induced severe acute respiratory syndrome coronavirus 2 antibody response and the path to accelerating development (Determining a Correlate of Protection). Clin. Lab. Med. 42, 111–128 (2022).
Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. https://doi.org/10.1111/imr.13091 (2022).
Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133–146 (2023).
Project NextGen: Next Generation Medical Countermeasures. US Department of Health and Human Services https://medicalcountermeasures.gov/nextgen (2025).
Bussink-Voorend, D., Hautvast, J. L. A., Vandeberg, L., Visser, O. & Hulscher, M. E. J. L. A systematic literature review to clarify the concept of vaccine hesitancy. Nat. Hum. Behav. 6, 1634–1648 (2022).
Cascini, F., Pantovic, A., Al-Ajlouni, Y., Failla, G. & Ricciardi, W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: a systematic review. EClinicalMedicine 40, 101113 (2021).
Chan, L. et al. Prior vaccination prevents overactivation of innate immune responses during COVID-19 breakthrough infection. Sci. Transl. Med. 17, eadq1086 (2025).
Cao, B. et al. Oral simnotrelvir for adult patients with mild-to-moderate Covid-19. N. Engl. J. Med. 390, 230–241 (2024).
Fan, X. et al. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. Lancet Infect. Dis. 24, 129–139 (2024).
Zhan, Y. et al. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. eClinicalMedicine 67, 102359 (2024).
Yotsuyanagi, H. et al. Efficacy and safety of 5-Day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw. Open 7, e2354991 (2024).
Lu, H. et al. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial. eClinicalMedicine 71, 102582 (2024).
World Health Organization. Coronavirus Disease (COVID-19). Strategy and Planning. WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-plans (2023).
